Great summary, Kat—I share your excitement about
Post# of 157614
That said, while the mouse data is very encouraging, it actually dates back to RP’s early days with the company and was first presented at NobelCon 2017, if I recall correctly. It highlights the critical role of CCR5 in metastasis, whether using maraviroc or leronlimab. Of course, we all know leronlimab stands apart—safer, without a black box warning, and as BP used to say, a much more “elegant molecule” in how it binds to CCR5 compared to maraviroc.
Onward and upward!

